Top-Rated Stocks NASDAQ:INSM Insmed - INSM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $21.79 +0.17 (+0.79%) (As of 02/2/2023 10:34 AM ET) Add Compare Share Share Today's Range$21.74▼$22.0950-Day Range$17.79▼$21.6952-Week Range$16.41▼$28.94Volume60,566 shsAverage Volume1.39 million shsMarket Capitalization$2.95 billionP/E RatioN/ADividend YieldN/APrice Target$43.36 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Insmed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside100.6% Upside$43.36 Price TargetShort InterestBearish7.95% of Shares Sold ShortDividend StrengthN/ASustainability-1.29Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$875,661 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.66) to ($3.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector442nd out of 1,030 stocksPharmaceutical Preparations Industry222nd out of 502 stocks 3.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.36, Insmed has a forecasted upside of 100.6% from its current price of $21.62.Amount of Analyst CoverageInsmed has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.95% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Insmed has recently increased by 0.75%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 71.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.29. Previous Next 2.8 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Insmed this week, compared to 2 articles on an average week.Search Interest7 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $875,661.00 in company stock.Percentage Held by InsidersOnly 4.63% of the stock of Insmed is held by insiders.Percentage Held by Institutions92.83% of the stock of Insmed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to decrease in the coming year, from ($3.66) to ($3.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -5.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -5.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInsmed has a P/B Ratio of 6.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Insmed (NASDAQ:INSM) StockInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Stock News HeadlinesJanuary 24, 2023 | finance.yahoo.comWall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to TradeJanuary 19, 2023 | finance.yahoo.comThe past five years for Insmed (NASDAQ:INSM) investors has not been profitableFebruary 2, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 16, 2023 | marketwatch.comCystic Fibrosis Therapeutics Market Size 2023 with Far-reaching scope to cover all the potential segments selection every stakeholderJanuary 6, 2023 | finance.yahoo.comInsmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comInsmed To Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 23, 2022 | finance.yahoo.comInsmed Incorporated (INSM) Stock Historical Prices & Data - Yahoo FinanceDecember 10, 2022 | cnbc.comBank of America says these stocks have the most 'potential upside' this holiday seasonFebruary 2, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. December 8, 2022 | cnbc.comThis biotech stock can jump more than 90%, Barclays saysDecember 8, 2022 | markets.businessinsider.comAnalyst Ratings for InsmedNovember 30, 2022 | finance.yahoo.comInsmed To Present at the Nasdaq 47th Investor ConferenceNovember 5, 2022 | benzinga.comInsmed Director Trades Company's StockNovember 5, 2022 | msn.comInsmed's Return On Capital Employed OverviewNovember 1, 2022 | finance.yahoo.comInsmed To Present at Three November ConferencesOctober 28, 2022 | finance.yahoo.comInsmed Ranks No. 1 on Science's 2022 Top Biopharma Employers ListOctober 21, 2022 | seekingalpha.comInsmed inks financing deals to raise $500M; announces $275 common stock offeringOctober 19, 2022 | uk.investing.comWhy United Airlines Shares Are Trading Higher? Here Are 43 Stocks Moving In Wednesday's Mid-Day Session By Benzinga - Investing.com UKOctober 19, 2022 | seekingalpha.comINSM stock on watch after financing agreements to raise $500M (NASDAQ:INSM) - Seeking AlphaOctober 19, 2022 | finance.yahoo.comInsmed Announces Strategic Financings Totaling $775 MillionOctober 19, 2022 | finance.yahoo.comWhy Insmed's Shares Fell 14.7% on WednesdayOctober 19, 2022 | streetinsider.comForm 8-K INSMED Inc For: Oct 19 - StreetInsider.comOctober 18, 2022 | streetinsider.comVersanis Bio Appoints Kenneth Attie, M.D., and Aditya Venugopal, Ph.D., to Key Leadership Roles - StreetInsider.comOctober 13, 2022 | nasdaq.comAn Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 44% Undervalued - NasdaqOctober 13, 2022 | finance.yahoo.comInsmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022 - Yahoo FinanceOctober 13, 2022 | finance.yahoo.comInsmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022October 6, 2022 | businesswire.com2022 US, UK and Japan Nontuberculous Mycobacteria Market Size and Trend Report to 2031 - Players Include Revimmune, Novartis, Insmed and Nobelpharma - ResearchAndMarkets.com - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Company Calendar Last Earnings10/28/2021Today2/02/2023Next Earnings (Estimated)2/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.36 High Stock Price Forecast$53.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+99.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-434,650,000.00 Net Margins-179.37% Pretax Margin-178.86% Return on Equity-319.03% Return on Assets-39.09% Debt Debt-to-Equity Ratio18.24 Current Ratio4.59 Quick Ratio4.11 Sales & Book Value Annual Sales$188.46 million Price / Sales15.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.47 per share Price / Book6.28Miscellaneous Outstanding Shares135,480,000Free Float129,204,000Market Cap$2.95 billion OptionableOptionable Beta1.56 Social Links Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsGalapagosNASDAQ:GLPGIVERIC bioNASDAQ:ISEEHarmony BiosciencesNASDAQ:HRMYBausch Health CompaniesNYSE:BHCRevance TherapeuticsNASDAQ:RVNCView All CompetitorsInsiders & InstitutionsState of New Jersey Common Pension Fund DBought 33,142 shares on 2/1/2023Ownership: 0.094%Wolverine Asset Management LLCBought 10,400 shares on 2/1/2023Ownership: 0.000%Legato Capital Management LLCBought 36,980 shares on 2/1/2023Ownership: 0.027%Janney Montgomery Scott LLCBought 2,108 shares on 2/1/2023Ownership: 0.011%CWM LLCBought 1,337 shares on 2/1/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions INSM Stock - Frequently Asked Questions Should I buy or sell Insmed stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks. What is Insmed's stock price forecast for 2023? 9 Wall Street analysts have issued 12 month price targets for Insmed's stock. Their INSM share price forecasts range from $28.00 to $53.00. On average, they predict the company's stock price to reach $43.36 in the next twelve months. This suggests a possible upside of 100.6% from the stock's current price. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts. How have INSM shares performed in 2023? Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have increased by 8.2% and is now trading at $21.62. View the best growth stocks for 2023 here. When is Insmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023. View our INSM earnings forecast. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings data on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.13. The biopharmaceutical company earned $46.80 million during the quarter, compared to the consensus estimate of $49.23 million. Insmed had a negative net margin of 179.37% and a negative trailing twelve-month return on equity of 319.03%. The firm's revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.63) EPS. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN). What is Insmed's stock symbol? Insmed trades on the NASDAQ under the ticker symbol "INSM." Who are Insmed's major shareholders? Insmed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.77%), Peregrine Capital Management LLC (0.26%), Scout Investments Inc. (0.24%), Rice Hall James & Associates LLC (0.18%), Hennion & Walsh Asset Management Inc. (0.10%) and State of New Jersey Common Pension Fund D (0.09%). Insiders that own company stock include Alfred Altomari, Christine A Pellizzari, David R Brennan, John Drayton Wise, John Soriano, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Insmed's stock price today? One share of INSM stock can currently be purchased for approximately $21.62. How much money does Insmed make? Insmed (NASDAQ:INSM) has a market capitalization of $2.93 billion and generates $188.46 million in revenue each year. The biopharmaceutical company earns $-434,650,000.00 in net income (profit) each year or ($3.64) on an earnings per share basis. How many employees does Insmed have? The company employs 373 workers across the globe. How can I contact Insmed? Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381. This page (NASDAQ:INSM) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.